AEON Biopharma
AEON
26 hedge funds and large institutions have $103M invested in AEON Biopharma in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
82% more capital invested
Capital invested by funds: $56.8M → $103M (+$46.7M)
37% more funds holding
Funds holding: 19 → 26 (+7)
0.03% more ownership
Funds ownership: 0.32% → 0.35% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.52M |
| 2 |
Goldman Sachs
New York
|
+$1.51M |
| 3 |
Millennium Management
New York
|
+$563K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$562K |
| 5 |
State Street
Boston,
Massachusetts
|
+$498K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$2.01M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$10.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.67K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
26
Dupont Capital Management
Wilmington,
Delaware
| $35 | – | – | – |
|
27
Macquarie Group
Sydney, NSW 2000,
Australia
| $10 | +$9.41K | +13 | New |
|
|
28
UBS Group
Zurich,
Switzerland
| – | -$4.67K | -9 | Closed |
|
AEON Hedge Fund Activity: Q1 2024 in Review
26 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2024, worth a combined $103M — up 82% from $56.8M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new AEON positions and 1 closed out — a net gain of 7 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.52M. The largest seller was Polar Asset Management Partners, cutting an estimated $2.01M.
- 26 institutional investors held AEON Biopharma (AEON) as of Q1 2024, up from 19 in Q4 2023.
- Funds reported $103M of AEON Biopharma stock for Q1 2024, up 82% quarter-over-quarter.
- 8 funds opened new AEON Biopharma positions in Q1 2024 and 1 closed out, a net change of +7 holders.
- The largest AEON Biopharma buyer in Q1 2024 was Vanguard Group, an estimated $5.52M added.
- The largest AEON Biopharma seller in Q1 2024 was Polar Asset Management Partners, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2024.